NexthalerPart2-Reviewed-Revision-to-IJPharm.pdf (4.55 MB)
Download file

Optical diagnostics studies of air flow and powder fluidisation in Nexthaler®. Part II: Use of fluorescent imaging to characterise transient release of fines from a dry powder inhaler

Download (4.55 MB)
journal contribution
posted on 11.09.2018, 12:55 by C. Merusi, G. Brambilla, Edward LongEdward Long, Graham Hargrave, Hendrik VersteegHendrik Versteeg
© 2018 The fine particle fraction is a key indicator of therapeutic effectiveness of inhaled pharmaceutical aerosols. This paper presents a fluorescence imaging technique to visualise and characterise the emission of active pharmaceutical ingredient (API) fines in model formulations containing coarse lactose carrier and 1.5–2 μm diameter fluorescent microspheres (model API fines). A two-camera arrangement was used to acquire simultaneous images of spatial and temporal distribution of model API fines and fluidised powder formulation near the mouthpiece exit of a DPI. Digital image analysis showed that the model API fines were released along with the bulk of the powder dose. More rapidly accelerating airflows were found to cause earlier release of API fines. The fluorescence imaging technique analyses a substantial fraction of the aerosol plume and was found to provide effective time-resolved characterisation of the de-aggregation and release of API fines with consistent results across a wide range of model API concentrations. Future studies should demonstrate the usefulness of the fluorescence imaging technique across different formulations and DPI devices.

History

School

  • Mechanical, Electrical and Manufacturing Engineering

Published in

International Journal of Pharmaceutics

Volume

549

Issue

1-2

Pages

96 - 108

Citation

MERUSI, C. ... et al., 2018. Optical diagnostics studies of air flow and powder fluidisation in Nexthaler®. Part II: Use of fluorescent imaging to characterise transient release of fines from a dry powder inhaler. International Journal of Pharmaceutics, 549(1-2), pp. 96-108.

Publisher

© Elsevier

Version

AM (Accepted Manuscript)

Publisher statement

This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/

Acceptance date

10/07/2018

Publication date

2018

Notes

This paper was accepted for publication in the journal International Journal of Pharmaceutics and the definitive published version is available at https://doi.org/10.1016/j.ijpharm.2018.07.032.

ISSN

0378-5173

eISSN

1873-3476

Language

en